{"entity":{"type":"insider","cik":"0001315082","url":"/insider/0001315082","json_url":"/insider/0001315082.json","name":"RA Capital Healthcare Fund LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":1052,"n_filings":232,"first":"2006-12-29","last":"2026-08-14","span_basis":"filed_date"},"name_variants":[{"name":"RA Capital Healthcare Fund LP","source":"filing","n_filings":210,"first_seen":"2008-11-07","last_seen":"2026-08-14"},{"name":"RA Capital Biotech Fund LP","source":"filing","n_filings":22,"first_seen":"2006-12-29","last_seen":"2008-11-04"}],"transactions":[{"id":9276045,"accession":"0001231919-26-000938","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000938","line_url":"/filing/0001231919-26-000938","is_derivative":false,"issuer_cik":"0001984086","issuer_name":"Septerna, Inc.","issuer_ticker":"SEPN","issuer_name_source":null,"issuer_url":"/issuer/0001984086","owner_cik":null,"owner_name":"Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1493000.0,"shares_display":"1,493,000","price_per_share":42.5,"price_display":"42.50","price_state":"stated","total_value":63452500.0,"total_display":"63,452,500.00","total_whole":"63,452,500","shares_owned_after":4777415.0,"shares_owned_after_display":"4,777,415","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-12","filed_date":"2026-08-14","scope":"insider","n_lines":2},{"id":5750630,"accession":"0001231919-26-000817","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000817","line_url":"/filing/0001231919-26-000817#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund III, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24944.0,"shares_display":"24,944","price_per_share":9.93,"price_display":"9.93","price_state":"stated","total_value":247693.92,"total_display":"247,693.92","total_whole":"247,694","shares_owned_after":17329570.0,"shares_owned_after_display":"17,329,570","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-31","filed_date":"2026-07-31","scope":"insider"},{"id":5750628,"accession":"0001231919-26-000817","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000817","line_url":"/filing/0001231919-26-000817#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund III, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20824.0,"shares_display":"20,824","price_per_share":9.99,"price_display":"9.99","price_state":"stated","total_value":208031.76,"total_display":"208,031.76","total_whole":"208,032","shares_owned_after":17304626.0,"shares_owned_after_display":"17,304,626","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-29","filed_date":"2026-07-31","scope":"insider"},{"id":5921422,"accession":"0001231919-26-000808","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000808","line_url":"/filing/0001231919-26-000808#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; Shah Rajeev M.; RA Capital Healthcare Fund LP","owner_display_name":"RA Capital Nexus Fund III, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41319.0,"shares_display":"41,319","price_per_share":9.99,"price_display":"9.99","price_state":"stated","total_value":412776.81,"total_display":"412,776.81","total_whole":"412,777","shares_owned_after":17283802.0,"shares_owned_after_display":"17,283,802","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-24","filed_date":"2026-07-28","scope":"insider"},{"id":6042465,"accession":"0001231919-26-000791","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-26-000791","line_url":"/filing/0001231919-26-000791#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":59880.0,"shares_display":"59,880","price_per_share":9.96,"price_display":"9.96","price_state":"stated","total_value":596404.8,"total_display":"596,404.80","total_whole":"596,405","shares_owned_after":17242483.0,"shares_owned_after_display":"17,242,483","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-23","filed_date":"2026-07-23","scope":"insider"},{"id":6042458,"accession":"0001231919-26-000791","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000791","line_url":"/filing/0001231919-26-000791#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":84124.0,"shares_display":"84,124","price_per_share":9.93,"price_display":"9.93","price_state":"stated","total_value":835351.32,"total_display":"835,351.32","total_whole":"835,351","shares_owned_after":17182603.0,"shares_owned_after_display":"17,182,603","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-22","filed_date":"2026-07-23","scope":"insider"},{"id":6019489,"accession":"0001231919-26-000779","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001231919-26-000779","line_url":"/filing/0001231919-26-000779#line-6","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Parabilis Medicines, Inc.","issuer_ticker":"PBLS","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.; RA Capital Nexus Fund III, L.P.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Voting Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":47250.0,"shares_display":"47,250","price_per_share":29.77,"price_display":"29.77","price_state":"stated","total_value":1406632.5,"total_display":"1,406,632.50","total_whole":"1,406,633","shares_owned_after":26529686.0,"shares_owned_after_display":"26,529,686","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-22","filed_date":"2026-07-22","scope":"insider"},{"id":6042456,"accession":"0001231919-26-000791","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000791","line_url":"/filing/0001231919-26-000791#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":120582.0,"shares_display":"120,582","price_per_share":9.55,"price_display":"9.55","price_state":"stated","total_value":1151558.1,"total_display":"1,151,558.10","total_whole":"1,151,558","shares_owned_after":17098479.0,"shares_owned_after_display":"17,098,479","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-21","filed_date":"2026-07-23","scope":"insider"},{"id":6019486,"accession":"0001231919-26-000779","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001231919-26-000779","line_url":"/filing/0001231919-26-000779","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Parabilis Medicines, Inc.","issuer_ticker":"PBLS","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.; RA Capital Nexus Fund III, L.P.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Voting Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":65923.0,"shares_display":"65,923","price_per_share":29.24672481531484,"price_display":"29.25","price_state":"stated","total_value":1928031.84,"total_display":"1,928,031.84","total_whole":"1,928,032","shares_owned_after":26482436.0,"shares_owned_after_display":"26,482,436","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-21","filed_date":"2026-07-22","scope":"insider","n_lines":3},{"id":6019476,"accession":"0001231919-26-000779","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000779","line_url":"/filing/0001231919-26-000779","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Parabilis Medicines, Inc.","issuer_ticker":"PBLS","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.; RA Capital Nexus Fund III, L.P.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Voting Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":131420.0,"shares_display":"131,420","price_per_share":27.27809260386547,"price_display":"27.28","price_state":"stated","total_value":3584886.93,"total_display":"3,584,886.93","total_whole":"3,584,887","shares_owned_after":26383526.0,"shares_owned_after_display":"26,383,526","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-20","filed_date":"2026-07-22","scope":"insider","n_lines":2},{"id":5774919,"accession":"0001231919-26-000774","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000774","line_url":"/filing/0001231919-26-000774#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7882.0,"shares_display":"7,882","price_per_share":8.95,"price_display":"8.95","price_state":"stated","total_value":70543.9,"total_display":"70,543.90","total_whole":"70,544","shares_owned_after":16977927.0,"shares_owned_after_display":"16,977,927","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-17","filed_date":"2026-07-20","scope":"insider"},{"id":6155886,"accession":"0001231919-26-000776","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000776","line_url":"/filing/0001231919-26-000776#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Vor Biopharma Inc.","issuer_ticker":"VOR","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; Kolchinsky Peter; RA Capital Healthcare Fund LP","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":213.0,"shares_display":"213","price_per_share":19.75,"price_display":"19.75","price_state":"stated","total_value":4206.75,"total_display":"4,206.75","total_whole":"4,207","shares_owned_after":4501882.0,"shares_owned_after_display":"4,501,882","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-16","filed_date":"2026-07-21","scope":"insider"},{"id":5774917,"accession":"0001231919-26-000774","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000774","line_url":"/filing/0001231919-26-000774#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":152472.0,"shares_display":"152,472","price_per_share":8.93,"price_display":"8.93","price_state":"stated","total_value":1361574.96,"total_display":"1,361,574.96","total_whole":"1,361,575","shares_owned_after":16970045.0,"shares_owned_after_display":"16,970,045","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-16","filed_date":"2026-07-20","scope":"insider"},{"id":9276039,"accession":"0001231919-26-000790","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000790","line_url":"/filing/0001231919-26-000790#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6522.0,"shares_display":"6,522","price_per_share":8.94,"price_display":"8.94","price_state":"stated","total_value":58306.68,"total_display":"58,306.68","total_whole":"58,307","shares_owned_after":16817543.0,"shares_owned_after_display":"16,817,543","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-13","filed_date":"2026-07-23","scope":"insider"},{"id":6237709,"accession":"0001231919-26-000764","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000764","line_url":"/filing/0001231919-26-000764#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6552.0,"shares_display":"6,552","price_per_share":8.94,"price_display":"8.94","price_state":"stated","total_value":58574.88,"total_display":"58,574.88","total_whole":"58,575","shares_owned_after":16817573.0,"shares_owned_after_display":"16,817,573","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-13","filed_date":"2026-07-14","scope":"insider"},{"id":6237704,"accession":"0001231919-26-000764","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000764","line_url":"/filing/0001231919-26-000764#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15102.0,"shares_display":"15,102","price_per_share":8.97,"price_display":"8.97","price_state":"stated","total_value":135464.94,"total_display":"135,464.94","total_whole":"135,465","shares_owned_after":16811021.0,"shares_owned_after_display":"16,811,021","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-10","filed_date":"2026-07-14","scope":"insider"},{"id":5811522,"accession":"0001231919-26-000711","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000711","line_url":"/filing/0001231919-26-000711#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund III, L.P.; Shah Rajeev M.; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP","owner_display_name":"RA Capital Nexus Fund III, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1876.0,"shares_display":"1,876","price_per_share":8.98,"price_display":"8.98","price_state":"stated","total_value":16846.48,"total_display":"16,846.48","total_whole":"16,846","shares_owned_after":16795919.0,"shares_owned_after_display":"16,795,919","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-26","filed_date":"2026-06-29","scope":"insider"},{"id":5811520,"accession":"0001231919-26-000711","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000711","line_url":"/filing/0001231919-26-000711#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund III, L.P.; Shah Rajeev M.; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP","owner_display_name":"RA Capital Nexus Fund III, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31000.0,"shares_display":"31,000","price_per_share":8.88,"price_display":"8.88","price_state":"stated","total_value":275280.0,"total_display":"275,280.00","total_whole":"275,280","shares_owned_after":16794043.0,"shares_owned_after_display":"16,794,043","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-25","filed_date":"2026-06-29","scope":"insider"},{"id":5786601,"accession":"0001231919-26-000688","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000688","line_url":"/filing/0001231919-26-000688","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":416911.0,"shares_display":"416,911","price_per_share":0.35,"price_display":"0.35","price_state":"stated","total_value":145918.85,"total_display":"145,918.85","total_whole":"145,919","shares_owned_after":4268448.0,"shares_owned_after_display":"4,268,448","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-17","filed_date":"2026-06-22","scope":"insider","n_lines":2},{"id":6007783,"accession":"0001231919-26-000654","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001231919-26-000654","line_url":"/filing/0001231919-26-000654","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":149625.0,"shares_display":"149,625","price_per_share":0.37,"price_display":"0.37","price_state":"stated","total_value":55361.25,"total_display":"55,361.25","total_whole":"55,361","shares_owned_after":4657664.0,"shares_owned_after_display":"4,657,664","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-16","filed_date":"2026-06-16","scope":"insider","n_lines":2},{"id":5838796,"accession":"0001231919-26-000665","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000665","line_url":"/filing/0001231919-26-000665#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Hemab Therapeutics Holdings, Inc.","issuer_ticker":"COAG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":61523.0,"shares_display":"61,523","price_per_share":24.98,"price_display":"24.98","price_state":"stated","total_value":1536844.54,"total_display":"1,536,844.54","total_whole":"1,536,845","shares_owned_after":6444637.0,"shares_owned_after_display":"6,444,637","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-16","filed_date":"2026-06-17","scope":"insider"},{"id":5838792,"accession":"0001231919-26-000656","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-26-000656","line_url":"/filing/0001231919-26-000656#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":124893.0,"shares_display":"124,893","price_per_share":8.89,"price_display":"8.89","price_state":"stated","total_value":1110298.77,"total_display":"1,110,298.77","total_whole":"1,110,299","shares_owned_after":16763043.0,"shares_owned_after_display":"16,763,043","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-16","filed_date":"2026-06-16","scope":"insider"},{"id":6007777,"accession":"0001231919-26-000654","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001231919-26-000654","line_url":"/filing/0001231919-26-000654","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":128770.0,"shares_display":"128,770","price_per_share":0.39,"price_display":"0.39","price_state":"stated","total_value":50220.3,"total_display":"50,220.30","total_whole":"50,220","shares_owned_after":4797350.0,"shares_owned_after_display":"4,797,350","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-15","filed_date":"2026-06-16","scope":"insider","n_lines":2},{"id":5838794,"accession":"0001231919-26-000665","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000665","line_url":"/filing/0001231919-26-000665#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Hemab Therapeutics Holdings, Inc.","issuer_ticker":"COAG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6146.0,"shares_display":"6,146","price_per_share":24.89,"price_display":"24.89","price_state":"stated","total_value":152973.94,"total_display":"152,973.94","total_whole":"152,974","shares_owned_after":6383114.0,"shares_owned_after_display":"6,383,114","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-15","filed_date":"2026-06-17","scope":"insider"},{"id":5838788,"accession":"0001231919-26-000656","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000656","line_url":"/filing/0001231919-26-000656#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15414.0,"shares_display":"15,414","price_per_share":8.99,"price_display":"8.99","price_state":"stated","total_value":138571.86,"total_display":"138,571.86","total_whole":"138,572","shares_owned_after":16638150.0,"shares_owned_after_display":"16,638,150","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-15","filed_date":"2026-06-16","scope":"insider"},{"id":6007771,"accession":"0001231919-26-000654","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000654","line_url":"/filing/0001231919-26-000654","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":170441.0,"shares_display":"170,441","price_per_share":0.4,"price_display":"0.40","price_state":"stated","total_value":68176.4,"total_display":"68,176.40","total_whole":"68,176","shares_owned_after":4917566.0,"shares_owned_after_display":"4,917,566","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-12","filed_date":"2026-06-16","scope":"insider","n_lines":2},{"id":5838782,"accession":"0001231919-26-000656","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000656","line_url":"/filing/0001231919-26-000656#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":391019.0,"shares_display":"391,019","price_per_share":8.57,"price_display":"8.57","price_state":"stated","total_value":3351032.83,"total_display":"3,351,032.83","total_whole":"3,351,033","shares_owned_after":16622736.0,"shares_owned_after_display":"16,622,736","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-12","filed_date":"2026-06-16","scope":"insider"},{"id":5909121,"accession":"0001231919-26-000625","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-26-000625","line_url":"/filing/0001231919-26-000625#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":548580.0,"shares_display":"548,580","price_per_share":7.91,"price_display":"7.91","price_state":"stated","total_value":4339267.8,"total_display":"4,339,267.80","total_whole":"4,339,268","shares_owned_after":16231717.0,"shares_owned_after_display":"16,231,717","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-11","filed_date":"2026-06-11","scope":"insider"},{"id":5786598,"accession":"0001231919-26-000638","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001231919-26-000638","line_url":"/filing/0001231919-26-000638","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Parabilis Medicines, Inc.","issuer_ticker":"PBLS","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Voting Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21188750.0,"shares_display":"21,188,750","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":423775000.0,"total_display":"423,775,000.00","total_whole":"423,775,000","shares_owned_after":26285093.0,"shares_owned_after_display":"26,285,093","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-11","filed_date":"2026-06-15","scope":"insider","n_lines":2},{"id":5786591,"accession":"0001231919-26-000628","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001231919-26-000628","line_url":"/filing/0001231919-26-000628","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":262503.0,"shares_display":"262,503","price_per_share":0.38,"price_display":"0.38","price_state":"stated","total_value":99751.14,"total_display":"99,751.14","total_whole":"99,751","shares_owned_after":5076685.0,"shares_owned_after_display":"5,076,685","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-11","filed_date":"2026-06-11","scope":"insider","n_lines":2},{"id":5909119,"accession":"0001231919-26-000625","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000625","line_url":"/filing/0001231919-26-000625#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":103.0,"shares_display":"103","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":721.0,"total_display":"721.00","total_whole":"721","shares_owned_after":15683137.0,"shares_owned_after_display":"15,683,137","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-10","filed_date":"2026-06-11","scope":"insider"},{"id":5786587,"accession":"0001231919-26-000628","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001231919-26-000628","line_url":"/filing/0001231919-26-000628","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":45923.0,"shares_display":"45,923","price_per_share":0.37,"price_display":"0.37","price_state":"stated","total_value":16991.51,"total_display":"16,991.51","total_whole":"16,992","shares_owned_after":5321751.0,"shares_owned_after_display":"5,321,751","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-10","filed_date":"2026-06-11","scope":"insider","n_lines":2},{"id":5909116,"accession":"0001231919-26-000625","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000625","line_url":"/filing/0001231919-26-000625#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":479039.0,"shares_display":"479,039","price_per_share":6.91,"price_display":"6.91","price_state":"stated","total_value":3310159.49,"total_display":"3,310,159.49","total_whole":"3,310,159","shares_owned_after":15683034.0,"shares_owned_after_display":"15,683,034","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-09","filed_date":"2026-06-11","scope":"insider"},{"id":5786582,"accession":"0001231919-26-000628","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000628","line_url":"/filing/0001231919-26-000628","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":369800.0,"shares_display":"369,800","price_per_share":0.37,"price_display":"0.37","price_state":"stated","total_value":136826.0,"total_display":"136,826.00","total_whole":"136,826","shares_owned_after":5364623.0,"shares_owned_after_display":"5,364,623","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-09","filed_date":"2026-06-11","scope":"insider","n_lines":2},{"id":6019470,"accession":"0001231919-26-000521","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000521","line_url":"/filing/0001231919-26-000521#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Hemab Therapeutics Holdings, Inc.","issuer_ticker":"COAG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":996.0,"shares_display":"996","price_per_share":24.94,"price_display":"24.94","price_state":"stated","total_value":24840.24,"total_display":"24,840.24","total_whole":"24,840","shares_owned_after":6376968.0,"shares_owned_after_display":"6,376,968","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-20","filed_date":"2026-05-21","scope":"insider"},{"id":6019467,"accession":"0001231919-26-000521","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000521","line_url":"/filing/0001231919-26-000521#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Hemab Therapeutics Holdings, Inc.","issuer_ticker":"COAG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3802.0,"shares_display":"3,802","price_per_share":24.97,"price_display":"24.97","price_state":"stated","total_value":94935.94,"total_display":"94,935.94","total_whole":"94,936","shares_owned_after":6375972.0,"shares_owned_after_display":"6,375,972","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-19","filed_date":"2026-05-21","scope":"insider"},{"id":5931395,"accession":"0001231919-26-000495","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000495","line_url":"/filing/0001231919-26-000495#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Hemab Therapeutics Holdings, Inc.","issuer_ticker":"COAG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6387.0,"shares_display":"6,387","price_per_share":24.9,"price_display":"24.90","price_state":"stated","total_value":159036.3,"total_display":"159,036.30","total_whole":"159,036","shares_owned_after":6372170.0,"shares_owned_after_display":"6,372,170","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-12","filed_date":"2026-05-14","scope":"insider"},{"id":5921406,"accession":"0001231919-26-000485","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001231919-26-000485","line_url":"/filing/0001231919-26-000485#line-6","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":94432.0,"shares_display":"94,432","price_per_share":0.64,"price_display":"0.64","price_state":"stated","total_value":60436.48,"total_display":"60,436.48","total_whole":"60,436","shares_owned_after":5709858.0,"shares_owned_after_display":"5,709,858","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-12","filed_date":"2026-05-12","scope":"insider"}],"collapsed":true,"next_cursor":"2026-05-12|5921406","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001984086","name":"Septerna, Inc.","url":"/issuer/0001984086","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2024-10-30","last_seen":"2026-08-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001817241","name":"Artiva Biotherapeutics, Inc.","url":"/issuer/0001817241","role":"Director, Ten percent owner","n_filings":11,"first_seen":"2024-07-24","last_seen":"2026-07-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001657677","name":"Parabilis Medicines, Inc.","url":"/issuer/0001657677","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2026-06-15","last_seen":"2026-07-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001817229","name":"Vor Biopharma Inc.","url":"/issuer/0001817229","role":"Director, Ten percent owner","n_filings":11,"first_seen":"2021-02-09","last_seen":"2026-07-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001785530","name":"Werewolf Therapeutics, Inc.","url":"/issuer/0001785530","role":"Director, Ten percent owner","n_filings":8,"first_seen":"2021-05-06","last_seen":"2026-06-22"},{"type":"issuer","type_label":"ISSUER","cik":"0002114044","name":"Hemab Therapeutics Holdings, Inc.","url":"/issuer/0002114044","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2026-05-06","last_seen":"2026-06-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001720580","name":"Adicet Bio, Inc.","url":"/issuer/0001720580","role":"Ten percent owner","n_filings":1,"first_seen":"2026-04-13","last_seen":"2026-04-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001933414","name":"Mineralys Therapeutics, Inc.","url":"/issuer/0001933414","role":"Director","n_filings":4,"first_seen":"2023-02-16","last_seen":"2026-03-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001631574","name":"Wave Life Sciences Ltd.","url":"/issuer/0001631574","role":"Director, Ten percent owner","n_filings":6,"first_seen":"2015-11-18","last_seen":"2026-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0002023658","name":"Bicara Therapeutics Inc.","url":"/issuer/0002023658","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2024-09-18","last_seen":"2026-03-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001778922","name":"SpyGlass Pharma, Inc.","url":"/issuer/0001778922","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2026-02-11","last_seen":"2026-02-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001768446","name":"Climb Bio, Inc.","url":"/issuer/0001768446","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2021-08-16","last_seen":"2026-01-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001680581","name":"Fulcrum Therapeutics, Inc.","url":"/issuer/0001680581","role":"Ten percent owner","n_filings":6,"first_seen":"2022-12-16","last_seen":"2025-12-10"},{"type":"issuer","type_label":"ISSUER","cik":"0002036042","name":"Sionna Therapeutics, Inc.","url":"/issuer/0002036042","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2025-02-10","last_seen":"2025-11-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001835597","name":"PepGen Inc.","url":"/issuer/0001835597","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2022-05-12","last_seen":"2025-09-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001610618","name":"Cidara Therapeutics, Inc.","url":"/issuer/0001610618","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2025-06-30","last_seen":"2025-06-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001863127","name":"Tyra Biosciences, Inc.","url":"/issuer/0001863127","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2021-09-17","last_seen":"2025-06-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001817713","name":"Janux Therapeutics, Inc.","url":"/issuer/0001817713","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2021-06-16","last_seen":"2025-03-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001785173","name":"89bio, Inc.","url":"/issuer/0001785173","role":"Director, Ten percent owner","n_filings":10,"first_seen":"2019-11-13","last_seen":"2025-02-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001880438","name":"AN2 Therapeutics, Inc.","url":"/issuer/0001880438","role":"Ten percent owner","n_filings":7,"first_seen":"2022-03-31","last_seen":"2024-08-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001798749","name":"Aerovate Therapeutics, Inc.","url":"/issuer/0001798749","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-07-06","last_seen":"2024-06-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001782303","name":"Boundless Bio, Inc.","url":"/issuer/0001782303","role":"Ten percent owner","n_filings":1,"first_seen":"2024-04-04","last_seen":"2024-04-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001787400","name":"Nkarta, Inc.","url":"/issuer/0001787400","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2022-04-28","last_seen":"2024-03-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001671858","name":"ARS Pharmaceuticals, Inc.","url":"/issuer/0001671858","role":"Director","n_filings":3,"first_seen":"2023-08-31","last_seen":"2024-03-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001815776","name":"LENZ Therapeutics, Inc.","url":"/issuer/0001815776","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2024-03-25","last_seen":"2024-03-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001707502","name":"Solid Biosciences Inc.","url":"/issuer/0001707502","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-03-23","last_seen":"2024-01-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001576885","name":"Acumen Pharmaceuticals, Inc.","url":"/issuer/0001576885","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-07-08","last_seen":"2023-07-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001701541","name":"Black Diamond Therapeutics, Inc.","url":"/issuer/0001701541","role":"Director","n_filings":1,"first_seen":"2023-07-07","last_seen":"2023-07-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001645569","name":"DICE Therapeutics, Inc.","url":"/issuer/0001645569","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2021-09-20","last_seen":"2023-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001672619","name":"IMARA Inc.","url":"/issuer/0001672619","role":"Ten percent owner","n_filings":5,"first_seen":"2020-03-17","last_seen":"2023-01-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001781174","name":"Acrivon Therapeutics, Inc.","url":"/issuer/0001781174","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2022-11-21","last_seen":"2022-11-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001479419","name":"Kala Pharmaceuticals, Inc.","url":"/issuer/0001479419","role":"Director, Ten percent owner, Other","n_filings":5,"first_seen":"2017-07-26","last_seen":"2022-05-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001786255","name":"Icosavax, Inc.","url":"/issuer/0001786255","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-08-04","last_seen":"2022-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001831915","name":"Cytek Biosciences, Inc.","url":"/issuer/0001831915","role":"Director, Ten percent owner","n_filings":8,"first_seen":"2021-07-29","last_seen":"2022-03-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001811764","name":"Therapeutics Acquisition Corp.","url":"/issuer/0001811764","role":"Director","n_filings":1,"first_seen":"2021-06-30","last_seen":"2021-06-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001604950","name":"scPharmaceuticals Inc.","url":"/issuer/0001604950","role":"Ten percent owner","n_filings":4,"first_seen":"2019-04-15","last_seen":"2021-03-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001783183","name":"Phathom Pharmaceuticals, Inc.","url":"/issuer/0001783183","role":"Ten percent owner","n_filings":3,"first_seen":"2020-03-31","last_seen":"2021-03-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001692830","name":"Satsuma Pharmaceuticals, Inc.","url":"/issuer/0001692830","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2019-09-17","last_seen":"2021-03-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001649904","name":"RHYTHM PHARMACEUTICALS, INC.","url":"/issuer/0001649904","role":"Ten percent owner, Other","n_filings":3,"first_seen":"2020-06-29","last_seen":"2020-12-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001748907","name":"Orchard Therapeutics plc","url":"/issuer/0001748907","role":"Ten percent owner","n_filings":1,"first_seen":"2020-11-06","last_seen":"2020-11-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001315082","retrieved_at":"2026-08-23T17:33:46+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}